Topics

Antibody Monotherapy Shows Promise in Neuromyelitis Optica

16:49 EDT 12 Sep 2019 | Medscape

Satralizumab as monotherapy is effective vs placebo for reducing risk of relapses in patients with autoimmune neuromyelitis optica spectrum disorder (NMOSD), new research suggests.
Medscape Medical News

Original Article: Antibody Monotherapy Shows Promise in Neuromyelitis Optica

NEXT ARTICLE

More From BioPortfolio on "Antibody Monotherapy Shows Promise in Neuromyelitis Optica"

Quick Search

Relevant Topic

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...